The framework: what gastritis recovery actually requires
Before comparing products, the comparison criteria need to be clear. For chronic H. pylori-driven gastritis, there are three mechanistic requirements for structural recovery:
- Urease inhibition / bacterial targeting. H. pylori uses urease to survive stomach acid. Without inhibiting this enzyme, the bacteria persists and the inflammatory cascade runs indefinitely. This is the primary driver that must be addressed.
- NF-kB / cytokine cascade reduction. H. pylori activates NF-kB, producing IL-8 and other cytokines that drive mucosal damage. Reducing this cascade reduces the ongoing tissue destruction and removes the primary suppressor of the repair pathway.
- EGFR/ERK mucosal repair activation. The stomach's repair pathway needs to be actively supported — goblet cell regeneration and mucus layer rebuilding require EGFR/ERK signalling, which is suppressed in active gastritis.
A supplement addressing only one of these creates conditions for partial improvement. A supplement addressing all three creates the conditions for structural recovery.
The products compared
TumGard combines quercetin and myricetin (urease inhibition, NF-kB suppression) with licorice-derived glabridin (EGFR/ERK activation, anti-adhesion). It is the only supplement in this comparison designed specifically around the three-mechanism requirement for H. pylori-driven gastritis recovery.
Zinc carnosine (polaprezinc) has the strongest clinical evidence base among non-antibiotic gastroprotective supplements — Japanese trials at 75mg twice daily show measurable mucosal healing in peptic ulcer disease and gastritis. Zinc ions support goblet cell membrane stability; the carnosine component has mild antioxidant activity. Limited evidence for H. pylori urease inhibition; does not address NF-kB signalling directly.
DGL licorice removes glycyrrhizin — the constituent responsible for blood pressure effects — to make it safer for long-term use. The remaining compounds provide mucosal coating and mild anti-inflammatory activity. However, the deglycyrrhizination process significantly reduces or removes glabridin, the isoflavonoid responsible for EGFR/ERK activation. DGL is useful for symptomatic coating relief but lacks the mechanistic depth of whole licorice flavonoid extracts for structural mucosal repair.
Probiotics do not inhibit H. pylori directly or reduce NF-kB inflammation. Their role in gastritis is indirect: specific strains reduce H. pylori colonisation density when used alongside eradication therapy, and reduce antibiotic-associated side effects during triple therapy. They also support restoration of microbiome balance after antibiotic courses — a relevant benefit for post-treatment recovery.
Side-by-side comparison
| Mechanism | TumGard | Zinc Carnosine | DGL Licorice | Probiotics |
|---|---|---|---|---|
| Urease inhibition | ✓ Yes — quercetin, myricetin | Mild, limited evidence | ✗ No | ✗ No |
| NF-kB inhibition | ✓ Yes — quercetin | ✗ Not documented | Mild general effect | ✗ No |
| EGFR/ERK activation | ✓ Yes — glabridin | ✓ Yes — zinc ions | Reduced (glabridin removed) | ✗ No |
| Anti-adhesion | ✓ Yes — glabridin | ✗ No | ✗ No | ✗ No |
| Clinical trial evidence | Mechanism studies (Ye 2023, Laine 2008) | ✓ RCT data (Japanese trials) | Limited | General probiotic evidence |
| Price / 20-day supply | ₹799 | Variable | Variable | Variable |
| Money-back guarantee | 60 days | Varies by brand | Varies by brand | Varies by brand |
If you have a confirmed H. pylori diagnosis with significant symptoms, signs of a peptic ulcer (severe stomach pain, black or tarry stool, vomiting), or significant unexplained weight loss alongside gut symptoms — see a doctor first. Supplements address the mucosal biology; antibiotic eradication remains the standard of care for active H. pylori infection.
References
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Documents H. pylori-driven gastritis and the three-mechanism framework for recovery — foundational reference for the comparison criteria in this guide.
- Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Modulating role of nuclear factor-κB in the gastroprotective action of flavonoids. Journal of Ethnopharmacology. 2023. PMID 36842733. Documents quercetin NF-kB inhibitory activity and glabridin EGFR/ERK activation in gastric tissue — the mechanistic basis for TumGard's scorecard in this comparison.
- Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defence and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Establishes EGFR/ERK as the primary mucosal repair pathway — the basis for scoring zinc carnosine and glabridin on repair mechanism.
- Watari I et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries. Journal of Gastroenterology and Hepatology. 2013;28(5):864–871. PMID 23441954. RCT demonstrating polaprezinc (zinc carnosine) mucosal healing efficacy — the clinical trial basis for zinc carnosine's evidence rating in this comparison.
The three-mechanism framework for comparison rests on published literature: urease inhibition (Crowe 2019), NF-kB inhibition by quercetin (Ye et al. 2023), and EGFR/ERK activation by glabridin (Ye et al. 2023; Laine et al. 2008). Zinc carnosine's mucosal repair evidence is drawn from clinical trials (Watari et al. 2013). The comparison is mechanism-based, not sales-based. TumGard's limitations (no direct clinical RCT as of 2026) are stated alongside its mechanisms.